WNS Recognized as a Leader in Procurement Transformation by NelsonHall
PTI
Last Updated:
Mumbai, Maharashtra, India & London, United Kingdom & New York, United States – Business Wire India
WNS (Holdings) Limited (NYSE: WNS), a digital-led business transformation and services company, today announced that WNS Procurement has been recognized as a 'Leader' in NelsonHall NEAT's 2025 Procurement Transformation evaluation.
According to NelsonHall, WNS Procurement specializes in transforming procurement functions and operating models to create integrated procurement ecosystems for its clients. The company was cited for its extensive knowledge across numerous indirect spend categories, ability to integrate procurement solutions with Finance & Accounting operations, and a strong client-centric and flexible approach to 'co-creating' custom solutions. The report also highlights WNS Procurement's capabilities and ongoing investments in AI-powered tools, platforms, and digital solutions.
'Leaders' in NelsonHall's NEAT methodology are characterized as having a combination of high capability to deliver immediate benefit and meet future requirements for clients relative to peers. Critical success factors included industry experience, change management capabilities, maturity of tools and digital accelerators.
'This recognition is further validation of WNS' ability to deliver truly transformative procurement services that go beyond mere cost optimization to become critical tools of growth. We are focused on enhancing our offerings by increasingly integrating AI and advanced analytics into our offerings to enable real-time insights for facilitating better sourcing decisions and improved client outcomes," said Keshav R. Murugesh, Group CEO, WNS.
'WNS Procurement is transforming procurement by combining advisory capabilities, category expertise, and Gen AI-powered platforms to drive tangible business outcomes. With recent acquisitions, a sharp focus on upstream procurement, consulting-led engagements, and its digital suites, WNS is well-positioned as a leader in procurement transformation with a strong appetite for growth," said Vaibhav Wardhan, Principal Analyst, NelsonHall.
WNS' Procurement Transformation services include sourcing, category management, sourcing support, and downstream procurement services. Its offerings are aligned across industry verticals and cover media, retail, CPG, manufacturing, insurance, healthcare, travel and hospitality, utilities and energy, banking and financial services, shipping and logistics, and hi-tech and knowledge services. WNS Procurement combines the power of WNS with our acquisitions of Denali, The SmartCube, and Optibuy to deliver domain-centric, digitally-led end-to-end procurement services and solutions.
About NelsonHall
NelsonHall is the leading global analyst firm dedicated to helping organizations understand the 'art of the possible' in digital operations transformation. With analysts in the U.S., Europe, and India, NelsonHall provides buy-side organizations with detailed, critical information on markets and vendors (including NEAT assessments) that helps them make fast and highly informed sourcing decisions. And for vendors, NelsonHall provides deep knowledge of market dynamics and user requirements to help them hone their go-to-market strategies. NelsonHall's analysis is based on rigorous, primary research, and is widely respected for the quality and depth of its insight.
About WNS
WNS (Holdings) Limited (NYSE: WNS) is a digital-led business transformation and services company. WNS combines deep domain expertise with talent, technology, and AI to co-create innovative solutions for over 700 clients across various industries. WNS delivers an entire spectrum of solutions including industry-specific offerings, customer experience services, finance and accounting, human resources, procurement, and research and analytics to re-imagine the digital future of businesses. As of June 30, 2025, WNS had 66,085 professionals across 65 delivery centers worldwide including facilities in Canada, China, Costa Rica, India, Malaysia, the Philippines, Poland, Romania, South Africa, Sri Lanka, Turkey, the United Kingdom, and the United States.
Safe Harbor Provision
This document includes information which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events. Factors that could cause actual results to differ materially from those expressed or implied are discussed in our most recent Form 10-K and other filings with the Securities and Exchange Commission. WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
(Disclaimer: The above press release comes to you under an arrangement with Business Wire India and PTI takes no editorial responsibility for the same.). PTI
First Published:
July 31, 2025, 18:15 IST
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 days ago
- Time of India
Agentic AI rises: 86% see higher risks, only 2% meet responsible AI gold standards
Infosys Knowledge Institute (IKI),the research arm of Infosys (NSE, BSE, NYSE: INFY), a global leader in next-generation digital services and consulting, today unveiled critical insights into the state of responsible AI (RAI) implementation across enterprises, particularly with the advent of agentic AI . The report, Responsible Enterprise AI in the Agentic Era, surveyed over 1,500 business executives and interviewed 40 senior decision-makers across Australia, France, Germany, UK, US, and New Zealand. The findings show that while 78% of companies see RAI as a business growth driver, only 2% have adequate RAI controls in place to safeguard against reputational risk and financial loss. The report analyzed the effects of risks from poorly implemented AI, such as privacy violations, ethical violations, bias or discrimination, regulatory non-compliance, inaccurate or harmful predictions, among others. It found that 77% of organizations reported financial loss, and 53% of organizations have suffered reputational impact from such AI related incidents. Key findings include: AI risks are widespread and can be severe 95% of C-suite and director-level executives report AI-related incidents in the past two years.39% characterize the damage experienced from such AI issues as 'severe' or 'extremely severe'.86% of executives aware of agentic AI believe it will introduce new risks and compliance issues. Responsible AI (RAI) capability is patchy and inefficient for most enterprises Only 2% of companies (termed 'RAI leaders') met the full standards set in the Infosys RAI capability benchmark — termed 'RAISE BAR' with 15% (RAI followers) meeting three-quarters of the 'RAI leader' cohort experienced 39% lower financial losses and 18% lower severity from AI do several things better to achieve these results including developing improved AI explainability, proactively evaluating and mitigating against bias, rigorously testing and validating AI initiatives and having a clear incident response plan. Executives view RAI as a growth driver 78% of senior leaders see RAI as aiding their revenue growth and 83% say that future AI regulations would boost, rather than inhibit, the number of future AI on average companies believe they are underinvesting in RAI by 30%. With the scale of enterprise AI adoption far outpacing readiness, companies must urgently shift from treating RAI as a reactive compliance obligation to embracing it proactively as a strategic advantage. To help organizations build scalable, trusted AI systems that fuel growth while mitigating risk, Infosys recommends the following actions: Learn from the leaders: Study the practices of high-maturity RAI organizations who have already faced diverse incident types and developed robust product agility with platform governance: Combine decentralized product innovation with centralized RAI guardrails and RAI guardrails into secure AI platforms: Use platform-based environments that enable AI agents to operate within preapproved data and a proactive RAI office: Create a centralized function to monitor risk, set policy, and scale governance with tools like Infosys' AI3S (Scan, Shield, Steer). Balakrishna D.R., EVP – Global Services Head, AI and Industry Verticals, Infosys said, 'Drawing from our extensive experience working with clients on their AI journeys, we have seen firsthand how delivering more value from enterprise AI use cases, would require enterprises to first establish a responsible foundation built on trust, risk mitigation, data governance, and sustainability. This also means emphasizing ethical, unbiased, safe, and transparent model development. To realize the promise of this technology in the agentic AI future, leaders should strategically focus on platform and product-centric enablement, and proactive vigilance of their data estate. Companies should not discount the important role a centralized RAI office plays as enterprise AI scales, and new regulations come into force.' Jeff Kavanaugh, Head of Infosys Knowledge Institute, Infosys, said, 'Today, enterprises are navigating a complex landscape where AI's promise of growth is accompanied by significant operational and ethical risks. Our research clearly shows that while many are recognizing the importance of Responsible AI, there's a substantial gap in practical implementation. Companies that prioritize robust, embedded RAI safeguards will not only mitigate risks and potentially reduce financial losses but also unlock new revenue streams and thrive as we transition into the transformative agentic AI era.'
Economic Times
4 days ago
- Economic Times
Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Reuters Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market. Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry dynamics. On July 29, 2025, Novo Nordisk lowered its full-year 2025 sales growth forecast from 13–21% to 8–14%. Operating profit (EBIT) growth was also trimmed to 10–16% from 16–24%. The announcement triggered a 20–30% single-day stock plunge, wiping out roughly $70 billion in market capitalization. Investors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting rapidly. Novo Nordisk's blockbuster drugs Wegovy and Ozempic have faced growing headwinds: Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales. —driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference. These trends highlight a dual threat: traditional competition and unregulated compounding pharmacies undermining pricing power. Longtime CEO Lars Fruergaard Jørgensen stepped down on August 7, 2025, passing the reins to Maziar Mike Doustdar. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor confidence. Market watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his vision. Novo Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth prospects. Financial institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.' Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global expansion. Novo Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting rights. Headquartered in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around $305 billion, although last year it briefly touched almost $600 billion, putting it among the most valuable companies on the planet. At home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease treatments. Despite short-term headwinds, Novo Nordisk is pursuing multiple growth avenues: Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump. CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients. Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption. $2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases. Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence. NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk. Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types. AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies. These developments suggest Novo's core capabilities remain strong, providing potential long-term catalysts. Not exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising pipeline. Short-term turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for recovery. Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer. Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs. Novo Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper transformation. Q1: What caused the Novo Nordisk stock plunge recently? A1: The stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded versions. Q2: How is Wegovy Ozempic market pressure affecting Novo Nordisk? A2: Competing drugs and pharmacy compounding have reduced market share and investor confidence.
Hans India
4 days ago
- Hans India
IBM unveils new India Client Experience Centre in Mumbai and announces plans to support Government of Maharashtra's Quantum Initiatives
Today, IBM (IBM: NYSE) announced the opening of the company's new IBM India Client Experience Center in Mumbai. As part of the facility's mission to support Indian enterprises' use of AI, hybrid cloud, and quantum computing, the company has signed a Letter of Intent (LOI) with the Government of Maharashtra to identify opportunities of support for the state's quantum initiatives. The LOI outlines areas of exploration that may include providing insight, knowledge, and expertise the state may use to help craft its own quantum initiative, and contributing to the development of the state's quantum ecosystem through workshops and other skills development efforts. Inaugurating the center, Shri Devendra Fadnavis, Hon'ble Chief Minister of Maharashtra said, 'With AI, quantum computing, and semiconductors, we are building a Viksit Maharashtra and Viksit Bharat. These technologies can accelerate sustainability and efficiency across sectors, creating new opportunities for growth and progress. Through our collaboration with IBM, we will harness quantum innovation to transform lives, while building a skilled talent pool to democratize its benefits and make them accessible to every citizen of the state.' Hans Dekkers, General Manager, IBM Asia Pacific said, 'IBM India Client Experience Centre reinforces our commitment in helping advance India's journey in AI, hybrid cloud, and quantum computing. Our interest in helping the Government of Maharashtra build their own vibrant quantum ecosystem exemplifies our commitment.' 'IBM welcomes the opportunity to engage with the Government of Maharashtra on advancing quantum computing skills in the state, in alignment with the country's National Quantum Mission, and vision of Viksit Bharat,' said Sandip Patel, Managing Director, IBM India and South Asia.
